What is Exogenesis?
Exogenesis is a private, venture-capital-backed entity that has pioneered a proprietary technology for modifying and controlling surfaces without the need for coatings or sub-surface damage. Its platform technology, NanoAccel, leverages Accelerated Neutral Atom Beam (ANAB) and Gas Cluster Ion Beam (GCIB) technologies to manipulate material surfaces at a nanoscale. This innovative approach is poised for application across a wide spectrum of biomedical, optical, and semiconductor sectors, offering unique advantages in material science.
How much funding has Exogenesis raised?
Exogenesis has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Exogenesis?
With a substantial total funding amount of $150K and a recent strategic investment, Exogenesis is well-positioned for accelerated growth and market penetration. The company's focus on advanced surface modification technologies suggests a trajectory towards scaling its operations, expanding its research and development capabilities, and forging strategic partnerships. This late-stage funding likely signals a move towards commercialization and broader adoption of its NanoAccel platform, aiming to capture significant market share in its target industries.
See full Exogenesis company page
